RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2010; 103(01): 34-39
DOI: 10.1160/TH09-06-0361
DOI: 10.1160/TH09-06-0361
Viewpoint Article
The clinical implications of new oral anticoagulants: Will the potential advantages be achieved?
Authors
Weitere Informationen
Publikationsverlauf
Received:
11. Juni 2009
Accepted after major revision:
15. Oktober 2009
Publikationsdatum:
22. November 2017 (online)
-
References
- 1 Ansell J. et al. The pharmacology and management of the vitamin K antagonists: ACCP evidence-based clinical practice guidelines. Chest 2008; 133: 160S-198S.
- 2 Budnitz DS. et al. National surveillance of emergency department visits for outpatient adverse drug events. J Am Med Assoc 2006; 296: 1858-1866.
- 3 Santell JP. et al. Top 10 drug products involved in medication errors. Available at: www.usp.org/pdf/EN/patientSafety/drugSafetyReview2003–12–08.pdf
- 4 Weitz JI. et al. New Antithrombotic Drugs. Chest 2008; 133: 234S-256S.
- 5 Eriksson BI. et al. Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Developtment. Clin Pharmacokinet 2009; 48: 1-22.
- 6 Agnelli G. et al. ODIXa-DVT Study Investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116: 180-187.
- 7 Spyropoulos AC. Brave new world: The current and future use of novel anticoagulants. Thromb Res 2008; 123: 29-35.
- 8 Executive Steering Committee on behalf of the SPORTIF III Investigators.. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003; 362: 1691-1698.
- 9 SPORTIF Executive Steering Committee for the SPORTIF V Investigators.. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. J Am Med Assoc 2005; 293: 690-698.
- 10 Fiessinger JN. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. J Am Med Assoc 2005; 293: 681-689.
- 11 Wallentin L. et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomized controlled trial. Lancet 2003; 362: 789-797.
- 12 RE-MODEL Study Group: Eriksson BI. Dahl OE. Rosencher N, et al. Oral dabigatran etexilate vs. sub-cutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 05: 2178-2185.
- 13 RE-NOVATE Study Group:. Eriksson BI, Dahl OE, Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
- 14 RE-MOBILIZE Writing Committee:. Ginsberg JS, Davidson BL, Comp PC. et al. Oral thrombin inhibitor Dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
- 15 Connolly SJ. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
- 16 RECORD1 Study Group:. Eriksson BI, Borris LC, Friedman RJ. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
- 17 RECORD2 Investigators:. Kakkar AK, Brenner B, Dahl OE. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial. Lancet 2008; 372: 31-39.
- 18 RECORD3 Investigators:. Lassen MR, Ageno W, Borris LC. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
- 19 Turpie AGG. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomized trial. Lancet 2009; 373: 1673-1680.
- 20 Turpie AGG. et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopedic surgery: effect on symptomatic venous thromboembolism, death, and bleeding. Blood (ASH Annual Meeting Abstracts) 2008; 112: 18-19 (Abstract 36).
- 21 Lassen M. et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
- 22 Lassen MR. et al. The ADVANCE 2 study: A randomized double-blind trial comparing apixaban with enoxaparin for thromboprophylaxis after total knee replacement. J Thromb Haemost. 2009 7 (Suppl. 2): Abstract #LB-MO-005.
- 23 Blech S. et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399.
- 24 Kubitza D. et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939– an oral, direct Factor Xa inhibitor- after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
- 25 Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 274-284.
- 26 Stangier J. et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
- 27 Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs 2008; 09: 1020-1033.
- 28 Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295.
- 29 Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28: 380-386.
- 30 DiMatteo MR. et al. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40: 794-811.
- 31 Cramer JA. Partial medication compliance: the enigma in poor medical outcomes. Am J Manag Care 1995; 01: 167-174.
- 32 Sullivan SD. et al. Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ 1990; 02: 19-33.
- 33 Dunbar-Jacob J. et al. Adherence in chronic disease. In: Annual review of nursing research. New York: Springer; 2000. 18 pp. 48-90.
- 34 Platt AB. et al. Risk factors for nonadherence to warfarin: results from the IN-RANGE study. Pharmcoepidemiology Drug Safety 2008; 17: 853-860.
- 35 Ansell JE. Optimizing the Efficacy and Safety of Oral Anticoagulant Therapy: High Quality Dose Management, Anticoagulation Clinics, and Patient Self-Management. Semin Vas Med 2003; 03: 261-269.
- 36 Kimmel SE. et al. The Influence of Patient Adherence on Anticoagulation Control with Warfarin : Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007; 167: 229-235.
- 37 Fox M. et al. Cash-strapped US Patients may be skipping drugs. Reuters. 2/10/09. http://www.reuters.com/article/healthNews/idUSTRE/5196SR20090211. Accessed on 2/11/09.